Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Inhaled TRL1068 in Healthy Volunteers
NCT07644195Phase 1Not yet recruiting
- Sponsor
- Trellis Bioscience
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of calpurbatug in bacterial infection (2 arms), sponsored by Trellis Bioscience. Primary endpoints: Incidence of abnormal physical exam findings at 30 days, Severity of abnormal physical exam findings at 30 days and 10 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
calpurbatug
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07644195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644195.